Loading
A phase 1/2 trial of Ivonescimab, Cadonilimab, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Akeso, active and no longer recruiting.
AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT05904379 by Akeso, with 233 participants planned, started 2023-07-13 and due to reach its primary completion in 2026-06-30. Interventions recorded: AK112, AK104, Carboplatin, paclitaxel, pemetrexed. Conditions listed: Advanced Non-small-cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Akeso, Ivonescimab, Bispecific antibodies, Carboplatin.
Shares Akeso, Ivonescimab, Bispecific antibodies, Docetaxel.
Shares Cadonilimab, Akeso, Bispecific antibodies, Pemetrexed.
Shares Cadonilimab, Akeso, Ivonescimab, Bispecific antibodies.
Shares Cadonilimab, Akeso, Ivonescimab, Bispecific antibodies.
Shares Cadonilimab, Akeso, Ivonescimab, Bispecific antibodies.
Shares Akeso, Pemetrexed, Docetaxel, Paclitaxel / nab-paclitaxel.
Shares Akeso, Ivonescimab, Paclitaxel / nab-paclitaxel, Carboplatin.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/